TRANSLATION PATENT COOPERATION TREATY PCT INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

1 **	nt's or agent's file reference 2003/008 PCT	FOR FURTHER ACTION	THER ACTION See Form PCT/IPEA/416						
	onal application No. /EP2004/012947	International filing date (day) 16.11.2004	ntional filing date (day/month/year) Priority date (day/month/year) 11.2004 05.12.2003						
	International Patent Classification (IPC) or national classification and IPC								
	F47/00, A61 M15								
Applicant LTS LOHMANN THERAPIE-SYSTEME AG									
1.	1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.								
2.	This REPORT consists of a tot	al of 7	_ sheets, including the	is cover sheet.					
3.	This report is also accompanied	d by ANNEXES, comprising:							
	a. (sent to the applica	nt and to the International Bureau) a	total of 5	sheets, as follows:					
	sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).								
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.									
b (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))									
	, containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see								
Section 802 of the Administrative Instructions).									
4.	This report contains indications	s relating to the following items:							
	Box No. I Basis	of the report							
	Box No. II Prior	ity							
	Box No. III Non-	establishment of opinion with regard	to novelty, inventive	step and industrial applicability					
	Box No. IV Lack	of unity of invention							
	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement								
	Box No. VI Certain documents cited								
	Box No. VII Certain defects in the international application								
	Box No. VIII Certain observations on the international application								
Date of s	submission of the demand	Date o	f completion of this re	port					
Name ar	nd mailing address of the IPEA/E	EP Author	Authorized officer						
			2.7						
Facsimil	le No.	Teleph	none No.						

Box No	. I	Basis of the report							
	_	d to the language, this report is based on the internation of the inte	onal application in the language in	which it was filed, unless otherwise					
	This report is based on translations from the original language into the following language which is the language of a translation furnished for the purposes of:								
	international search (Rule 12.3 and 23.1(b))								
	publication of the international application (Rule 12.4)								
		international preliminary examination (Rule 55.2 and	/or 55.3)						
re	_	d to the elements of the international application, this <i>Office in response to an invitation under Article 14 at</i>):	<u> </u>	•					
	the in	nternational application as originally filed/furnished							
	the d	escription:							
	pages	s <u>1-18</u>		as originally filed/furnished					
	pages	S*	received by this Authority on						
	pages	S*	_ received by this Authority on						
\triangleright	the cl	laims:							
	nos.			as originally filed/furnished					
	nos.*		as amended (togethe	er with any statement) under Article 19					
	nos.*		received by this Authority on	16.08.2005 with letter					
	nos.*								
\triangleright	7								
		rawings:							
	sheet			as originally filed/furnished					
	sheet		_						
_	sheet ¬	S*	_ received by this Authority on						
	☐ a seq	uence listing and/or any related table(s) – see Supplen	nental Box Relating to Sequence L	Listing.					
3.	The a	amendments have resulted in the cancellation of:							
		the description, pages							
		the claims, nos.							
		41 4							
		the sequence listing (specify):							
		any table(s) related to sequence listing (specify):							
4.		report has been established as if (some of) the amend have been considered to go beyond the disclosure as fa							
		the description, pages							
		the claims, nos.							
		the drawings, sheets/figs							
	the sequence listing (specify): any table(s) related to sequence listing (specify):								
* If	item 4 ar	oplies, some or all of those sheets may be marked "sup							

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability									
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:									
	the entire international application								
\boxtimes	claims Nos. 7,8,22,23								
because	2:								
	the said international application, or the said claims Nos.								
	relate to the following subject matter which does not require an international preliminary examination (specify):								
	the description, claims or drawings (indicate particular elements below) or said claims Nos. 7,8 are so unclear that no meaningful opinion could be formed (specify): See Supplemental Box								
	the claims, or said claims Nos.		are so inadequately supported						
	by the description that no meaningful opinion could be formed.								
	no international search report has been	established for said claims Nos. 22, 23							
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrat Instructions in that:								
	the written form	has not been furnished							
		does not comply with the standard							
	the computer readable form	has not been furnished							
	F	does not comply with the standard							
		d/or amino acid sequence listing, if in computer readable fo	orm only, do not comply with the						
	See Supplemental Box for further deta	Annex C-bis of the Administrative Instructions.							
	see supplemental box for futurel deta								

YES NO YES NO YES NO
NO YES NO YES
NO YES NO YES
YES NO YES
NO YES
YES

International application No.
PCT/EP2004/012947

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Document D3 discloses the features of the preamble of claim 1 (see column 2, lines 17-20).

The features of the characterizing part of claim 1 are not known from or suggested by the available prior art.

Claims 2-6 and 9-17 are dependent on claim 1 and are therefore likewise considered novel and inventive. The method claims 18-21 relate to a device according to claim 1 and are therefore likewise considered novel and inventive.

Box	No. VII		Certain defe	cts in th	e intern	ational app	olication						
The	following	, def	ects in the form	or cont	ents of t	he internation	onal appl	ication ha	ive been no	oted:			
	The	f∈	eatures	of	the	clain	ns ar	ce no	t foi	llowed	l by r	eferenc	ce
	sign	ıs	placed	bet	weer	n pare	enthe	eses	(PCT	Rule	6.2 (b)).	

International application No.
PCT/EP2004/012947

Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of: Box III.1

Claims 7 and 8 do not meet the requirements of PCT Article 6 because the subject matter for which protection is sought is not clearly defined. These claims attempt to define the subject matter in terms of the results to be achieved, but in so doing merely state the problem to be solved, without specifying the technical features necessary to achieve the result.

Claims 22 and 23 concern a method for the treatment of the human or animal body by therapy (PCT Rule 39.1(iv)), that is to say smoking cessation and the administration of the medical drugs Selegilin and mecamylamine (see page 2, lines 21 to 27).